source
- Ultragenyx to consider major cost cuts after Angelman drug fails trialUltragenyx announced that its experimental therapy GTX-102 (apazunersen) for Angelman syndrome failed to meet primary and secondary endpoints in a Phase 3 study. The company said there were no dif…
- Pfizer sells Seagen-derived ADC to Medicus Pharma for $12 million upfront, potential $1 billion milestonesPfizer has transferred rights to an antibody‑drug conjugate it acquired in its Seagen purchase to Medicus Pharma. Medicus will pay $12 million upfront and $15 million a year later, and Pfizer coul…